Abstract:Around 3-5% HIV-1-infected individuals develop high titers of broadly neutralizing HIV-1 antibodies (bnAbs) during chronic infection. However, monoclonal antibodies (mAbs) isolated from such "elite neutralizers" do not, in most cases, depict the serum IgGs in neutralizing the virus. We hypothesize that HIV-1-specific antibodies in infected subjects may work in a population manner in containing the virus in vivo, and in vitro reconstituted antibody repertoires of "elite neutralizers" may mimic the sera in binding and neutralizing the virus. This study aims to investigate the antibody repertoires of three such "elite neutralizers" by reconstituting the immune antibody repertories in vitro followed by a comparative study of the recombinant library IgGs with the corresponding serum IgGs. We found that the recombinant library IgGs were much weaker than the serum IgGs in binding to envelope glycoproteins (Envs) and in neutralizing the virus and inhibiting Env-mediated cell-cell fusion. However, the sorted libraries composing of HIV-1-specific neutralizing antibodies (nAbs) in the three recombinant libraries exhibited comparable binding and inhibitory activities, as well as antibody-dependent cell-mediated cytotoxicity (ADCC), to the serum IgGs. The sorted library IgGs further showed neutralization profiles which are similar to those of the serum IgGs, but they were overall less potent than the serum IgGs. The sorted library IgGs and the serum IgGs bound weakly to the resurfaced Env gp120, RSC3, and did not bind to the CD4 binding site (CD4bs) knock-out mutant, ΔRSC3. Profiling with VRC01 binding site knock-out site mutants of gp120BaL indicates that, if there are any CD4bs bnAbs in these sera, they are more likely b12-like, but not VRC01-class bnAbs. Our results suggest that HIV-1-specific Ab-expressing B cells, especially potent nAb-expressing B cells may not be rich in the B cell repertoires of "elite neutralizers", but they may be highly active in producing nAbs in vivo. In vitro reconstituted HIV-1 nAb repertoires of "elite neutralizers" may be used in passive immunization to prevent HIV-1 infection. HIV-1 vaccine immunogens may be designed to target multiple neutralizing determinants to stimulate multiple B cell populations. HIV-1-specific antibodies induced by such immunogens may work in combination or synergistically in containing the virus.

The Potential Of The Human Immune System To Develop Broadly Neutralizing Hiv-1 Antibodies: Implications For Vaccine Development

Cross-Reactive Human Igm-Derived Monoclonal Antibodies That Bind to Hiv-1 Envelope Glycoproteins

Potent and Broad HIV-neutralizing Antibodies in Memory B Cells and Plasma

E108 Analysis of Broad Neutralizing B Cell Lineages to Guide HIV-1 Immunogen Design

Reconstitution and Characterization of Antibody Repertoires of HIV-1-infected "elite Neutralizers".

A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses

Analysis of Memory B Cell Responses and Isolation of Novel Monoclonal Antibodies with Neutralizing Breadth from HIV-1-Infected Individuals

A vaccine strategy for inducing broadly neutralizing antibodies against HIV

Broadly neutralizing antibodies against human immunodeficiency virus type 1(HIV-1) and rational design of HIV-1 vaccines

Development of Neutralization Breadth against Diverse HIV‐1 by Increasing Ab–Ag Interface on V2

Immunoglobulin Gene Insertions and Deletions in the Affinity Maturation of HIV-1 Broadly Reactive Neutralizing Antibodies.

Cooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies

Staged Induction of HIV-1 Glycan–dependent Broadly Neutralizing Antibodies

Immune Perturbations in HIV-1–infected Individuals Who Make Broadly Neutralizing Antibodies

Vaccination induces broadly neutralizing antibody precursors to HIV gp41

Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires.

Identification and specificity of broadly neutralizing antibodies against HIV

HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen

Antibody‐virus Co‐evolution in HIV Infection: Paths for HIV Vaccine Development

Initiation of Immune Tolerance–controlled HIV Gp41 Neutralizing B Cell Lineages

HIV-1 Antibodies from Infection and Vaccination: Insights for Guiding Vaccine Design